Pharmacological inhibition of Dyrk1B leads quiescent cancer cells to re-enter the cell cycle, rendering them vulnerable to conventional cancer treatments, induces apoptosis in cancer cells, and reduces tumor size in vitro and in vivo. The gene discussed is DYRK1B; the disease is neoplasm.